CGEN (cgen.com) שווי פירמה כולל

Compugen Ltd. (CGEN) delegates initial drug trials to external contractors while retaining all patent rights. The business relies on a digital biological target discovery system, where the confirmation of antibody efficacy serves as the key success factor. This daily price action on GURU.Markets shows that the Separate Enterprise Value is 55.33. Market capitalization is growing due to payments from pharma behemoths for the use of unique AI developments.

Analyzing historical EV levels allows for an assessment of Compugen Ltd. (CGEN) as a high-tech player in the immunotherapy sector. This metric determines the total acquisition cost of the business by summing market capitalization and debt minus liquid assets, which, combined with a unique protein modeling platform, confirms the high value of intellectual barriers and the fundamental resilience of the company.